The early DART blind spot: Why developmental toxicity needs a rethink in 2026

For decades, early drug discovery has advanced faster than our ability to meaningfully assess developmental toxicity risk before programs reach downstream stages. Biopharma teams are accelerating medicinal chemistry cycles, screening complex modalities with limited material, and advancing candidates under increasingly compressed timelines. Yet one of the many critical questions that remains notoriously difficult to answer early:

Will this candidate pose a developmental toxicity risk once it reaches in vivo studies, and will we know in time to act?

Most teams won’t know, until it may already be too late.

Traditional developmental and reproductive toxicology (DART) studies, while essential, occur later in the nonclinical pathway and require significant time and test material. This gap between early discovery and regulatory DART creates a blind spot that can derail programs, consume resources, and introduce avoidable late‑stage risk. Closing this early DART blind spot has become a strategic priority as scientific complexity, regulatory expectations, and development timelines continue to converge.

The early‑stage bottleneck: Emerging challenges for modern biopharma

Today’s R&D environment presents three compounding pressures:

These converging forces create a perfect storm: discovery teams need human‑relevant developmental toxicity indicators earlier, at a point when traditional models are impractical or time-consuming.

Why developmental toxicity is often a “late discovery”

The complexity of embryofetal development is one reason early prediction has historically been limited. Developmental toxicity reflects intricate interactions across maternal physiology, placental biology, and differentiating tissues, which are difficult to recapitulate with traditional early‑stage tools.

This means:

• Structural analogs that look promising may still carry hidden teratogenic risk
• Medicinal chemistry decisions may proceed without developmental context
• Programs may advance only to face late‑stage surprises

The scientific, operational, and financial costs are substantial.

The new industry question:

“How early is early enough?”

Biopharma organizations are increasingly seeking earlier human‑relevant hazard insight, and they’re asking more targeted questions:

• Can we screen developmental toxicity before selecting a lead?
• Could we prioritize analogs with a clearer understanding of developmental hazard?
• How can we avoid costly late‑stage pivots?
• What does regulatory alignment look like for early NAM adoption?

The industry is signaling a shift: early developmental toxicity insight isn’t a “nice‑to‑have”; it is becoming foundational to stronger nonclinical strategy.

NAMs are reshaping the front end of DART strategy

Scientific and regulatory momentum is accelerating the adoption of New Approach Methodologies (NAMs). NAMs offer the potential to deliver:

• Human‑relevant metabolomic or mechanistic readouts
• Rapid timelines compatible with medicinal chemistry cycles
• Low material needs suited to early research constraints
• Actionable, exposure‑based understanding of developmental toxicity potential

This approach aligns directly with the ICH S5(R3) framework, which recognizes NAMs that can inform, support, or in some cases defer in vivo studies when scientifically justified.

The implications are clear: early developmental toxicity assessment is no longer something teams “wait on”. It is becoming a strategic lever to move faster, reduce uncertainty, and build more robust weight‑of‑evidence packages from the very beginning.

Matching NAM approaches to early DART decisions

As early‐stage pipelines accelerate, many biopharma teams now face a more practical question than whether to adopt NAMs:

Which NAM approaches are appropriate for informing specific early DART decisions?

Different NAMs offer different types of insight, and understanding those differences is critical to using them effectively within a modern, tiered DART strategy.

These data can directly inform compound ranking, analog selection, and escalation decisions, helping teams determine where further in vivo investment is warranted.

Using NAMs together, not in isolation

Importantly, these NAM approaches are most powerful when used collectively. Computational tools help narrow focus, cell‑based assays provide biological context, and metabolomics‑driven NAMs deliver quantitative thresholds that support confident decision‑making.

Integrated into a tiered, weight of evidence framework, these approaches allow biopharma teams to screen earlier and prioritize more effectively. They also allow teams to approach downstream DART studies with greater clarity and regulatory alignment, without slowing program momentum.

The road ahead: A new standard for early insight

As biopharma organizations push toward faster, more efficient nonclinical pathways, the traditional gap between discovery and DART evaluation can no longer be treated as inevitable. The ability to understand developmental toxicity risk before committing to large‑scale in vivo programs will increasingly differentiate teams that move decisively from those forced into late corrective action.

Early, human‑relevant insight is quickly becoming the new standard, and organizations that embrace this shift now will be better positioned to:

• Prioritize smarter
• Reduce rework
• Avoid late‑stage surprises
• Strengthen IND‑enabling packages
• Maintain program velocity under increasing regulatory expectations
   

The industry is moving toward a new paradigm in which developmental toxicity is no longer a downstream unknown but a deliberate early‑stage decision point. For teams willing to rethink when developmental risk is evaluated, NAMs offer a practical path to earlier clarity and stronger nonclinical strategies from the outset.